Altered Ca2+ signaling in cancer cells: Proto-oncogenes and tumor suppressors targeting IP3 receptors

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1835, Issue 2, 2013, Pages 180-193

  Akl, Haidar ^a   Bultynck, Geert ^a  

^a LABORATORY OF MOLECULAR AND CELLULAR SIGNALING   (Belgium)

Author keywords

Intracellular Ca2+ signaling; IP3 receptors; Proto oncogenes; Tumor suppressors

Indexed keywords

BECLIN 1; CELL PROTEIN; CISPLATIN; INOSITOL 1,4,5 TRISPHOSPHATE RECEPTOR; PACLITAXEL; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN BI 1; PROTEIN KINASE B; PROTEIN KRAP; PROTEIN MCL 1; UNCLASSIFIED DRUG; VOLTAGE DEPENDENT ANION CHANNEL;

AKT GENE; APOPTOSIS; BCL 2 GENE; BCL XL GENE; BECLIN 1 GENE; BI 1 GENE; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CALCIUM SIGNALING; CALCIUM TRANSPORT; CANCER CELL CULTURE; CANCER RESISTANCE; CELL GROWTH; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CELL SURVIVAL; DRUG TARGETING; ENDOPLASMIC RETICULUM; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE REGULATORY NETWORK; GENE TARGETING; HUMAN; IP3R GENE; KRAP GENE; MCL 1 GENE; MITOCHONDRIAL DYNAMICS; MITOCHONDRION; OUTER MEMBRANE; PML GENE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTO ONCOGENE; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; BCL-X PROTEIN; CALCIUM SIGNALING; HUMANS; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; MEMBRANE PROTEINS; MICROFILAMENT PROTEINS; NEOPLASMS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENES; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84872528492     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2012.12.001     Document Type: Review

References (237)

1. 3 receptor-mitochondria connection in apoptosis and autophagy. Biochim. Biophys. Acta 2011, 1813:1003-1013.
2. Mekahli D., Bultynck G., Parys J.B., De Smedt H., Missiaen L. Endoplasmic-reticulum calcium depletion and disease. Cold Spring Harb. Perspect. Biol. 2011, 3.
3. 2+ signals in autophagy. Cell Calcium 2012, 52:44-51.
4. 2+ and apoptosis. Cell Calcium 2012, 52:36-43.
5. Vervliet T., Kiviluoto S., Bultynck G. ER stress and UPR through dysregulated ER Ca2+ homeostasis and signaling. Endoplasmic Reticulum Stress in Health and Disease 2012, 107-142. Springer, Netherlands. P. Agostinis, A. Samali (Eds.).
6. Zhivotovsky B., Orrenius S. Calcium and cell death mechanisms: a perspective from the cell death community. Cell Calcium 2011, 50:211-221.
7. Hetz C. The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat. Rev. Mol. Cell Biol. 2012, 13:89-102.
8. Giorgi C., Wieckowski M.R., Pandolfi P.P., Pinton P. Mitochondria associated membranes (MAMs) as critical hubs for apoptosis. Commun. Integr. Biol. 2011, 4:334-335.
9. Patergnani S., Suski J.M., Agnoletto C., Bononi A., Bonora M., De Marchi E., Giorgi C., Marchi S., Missiroli S., Poletti F., Rimessi A., Duszynski J., Wieckowski M.R., Pinton P. Calcium signaling around mitochondria associated membranes (MAMs). Cell Commun. Signal. 2011, 9:19.
10. Shoshan-Barmatz V., Zalk R., Gincel D., Vardi N. Subcellular localization of VDAC in mitochondria and ER in the cerebellum. Biochim. Biophys. Acta 2004, 1657:105-114.
11. Shoshan-Barmatz V., Israelson A. The voltage-dependent anion channel in endoplasmic/sarcoplasmic reticulum: characterization, modulation and possible function. J. Membr. Biol. 2005, 204:57-66.
12. Min C.K., Yeom D.R., Lee K.E., Kwon H.K., Kang M., Kim Y.S., Park Z.Y., Jeon H., Kim do H. Coupling of ryanodine receptor 2 and voltage-dependent anion channel 2 is essential for Ca2+ transfer from the sarcoplasmic reticulum to the mitochondria in the heart. Biochem. J. 2012, 447:371-379.
13. 2+ transfer from the ER to mitochondria: when, how and why. Biochim. Biophys. Acta 2009, 1787:1342-1351.
14. De Stefani D., Raffaello A., Teardo E., Szabo I., Rizzuto R. A forty-kilodalton protein of the inner membrane is the mitochondrial calcium uniporter. Nature 2011, 476:336-340.
15. Baughman J.M., Perocchi F., Girgis H.S., Plovanich M., Belcher-Timme C.A., Sancak Y., Bao X.R., Strittmatter L., Goldberger O., Bogorad R.L., Koteliansky V., Mootha V.K. Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporter. Nature 2011, 476:341-345.
16. 2+ uptake that regulates cell survival. Cell 2012, 151:630-644.
17. Sammels E., Parys J.B., Missiaen L., De Smedt H., Bultynck G. Intracellular Ca2+ storage in health and disease: a dynamic equilibrium. Cell Calcium 2010, 47:297-314.
18. 2+ transfer to mitochondria. Cell 2010, 142:270-283.
19. 3 receptor. Neuron 2010, 68:865-878.
20. Bonora M., Patergnani S., Rimessi A., De Marchi E., Suski J.M., Bononi A., Giorgi C., Marchi S., Missiroli S., Poletti F., Wieckowski M.R., Pinton P. ATP synthesis and storage. Purinergic Signal 2012, 8:343-357.
21. 3R. Nat. Cell Biol. 2005, 7:1021-1028.
22. Gorlich D., Rapoport T.A. Protein translocation into proteoliposomes reconstituted from purified components of the endoplasmic reticulum membrane. Cell 1993, 75:615-630.
23. Nicchitta C.V., Murphy E.C., Haynes R., Shelness G.S. Stage- and ribosome-specific alterations in nascent chain-Sec61p interactions accompany translocation across the ER membrane. J. Cell Biol. 1995, 129:957-970.
24. 2+ leakage from the ER. EMBO J. 2012, 31:3282-3296.
25. 2+ release and beyond. Apoptosis 2007, 12:951-968.
26. 2+ transfer in the control of apoptosis. Oncogene 2008, 27:6407-6418.
27. 2+-dependent control of the permeability properties of the mitochondrial outer membrane and voltage-dependent anion-selective channel (VDAC). J. Biol. Chem. 2006, 281:17347-17358.
28. Kroemer G., Galluzzi L., Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol. Rev. 2007, 87:99-163.
29. 2+ requirement for mitochondrial permeability transition pore (mPTP) opening. J. Biol. Chem. 2009, 284:20796-20803.
30. Jayaraman T., Marks A.R. T cells deficient in inositol 1,4,5-trisphosphate receptor are resistant to apoptosis. Mol. Cell. Biol. 1997, 17:3005-3012.
31. Assefa Z., Bultynck G., Szlufcik K., Nadif Kasri N., Vermassen E., Goris J., Missiaen L., Callewaert G., Parys J.B., De Smedt H. Caspase-3-induced truncation of type 1 inositol trisphosphate receptor accelerates apoptotic cell death and induces inositol trisphosphate-independent calcium release during apoptosis. J. Biol. Chem. 2004, 279:43227-43236.
32. Khan M.T., Bhanumathy C.D., Schug Z.T., Joseph S.K. Role of inositol 1,4,5-trisphosphate receptors in apoptosis in DT40 lymphocytes. J. Biol. Chem. 2007, 282:32983-32990.
33. Steinmann C., Landsverk M.L., Barral J.M., Boehning D. Requirement of inositol 1,4,5-trisphosphate receptors for tumor-mediated lymphocyte apoptosis. J. Biol. Chem. 2008, 283:13506-13509.
34. 2+ signalling. Biol. Cell 2008, 100:39-49.
35. 2+ release and apoptosis. Cell Death Dis. 2012, 3:e304.
36. Kiviluoto S., Akl H., Vervliet T., Bultynck G., Parys J.B., Missiaen L., De Smedt H. IP3 receptor-binding partners in cell-death mechanisms. Wiley Interdisciplinary Reviews: Membrane Transport and Signaling 2012.
37. 2+ for cancer cell proliferation and survival. Nat. Rev. Cancer 2008, 8:361-375.
38. 2+-dependent mitochondrial apoptosis. Mol. Cell 2009, 36:500-511.
39. Chipuk J.E., McStay G.P., Bharti A., Kuwana T., Clarke C.J., Siskind L.J., Obeid L.M., Green D.R. Sphingolipid metabolism cooperates with BAK and BAX to promote the mitochondrial pathway of apoptosis. Cell 2012, 148:988-1000.
40. Swinnen J.V., Brusselmans K., Verhoeven G. Increased lipogenesis in cancer cells: new players, novel targets. Curr. Opin. Clin. Nutr. Metab. Care 2006, 9:358-365.
41. Hirota J., Furuichi T., Mikoshiba K. Inositol 1,4,5-trisphosphate receptor type 1 is a substrate for caspase-3 and is cleaved during apoptosis in a caspase-3-dependent manner. J. Biol. Chem. 1999, 274:34433-34437.
42. Nakayama T., Hattori M., Uchida K., Nakamura T., Tateishi Y., Bannai H., Iwai M., Michikawa T., Inoue T., Mikoshiba K. The regulatory domain of the inositol 1,4,5-trisphosphate receptor is necessary to keep the channel domain closed: possible physiological significance of specific cleavage by caspase 3. Biochem. J. 2004, 377:299-307.
43. Boehning D., Patterson R.L., Sedaghat L., Glebova N.O., Kurosaki T., Snyder S.H. Cytochrome c binds to inositol (1,4,5) trisphosphate receptors, amplifying calcium-dependent apoptosis. Nat. Cell Biol. 2003, 5:1051-1061.
44. Boehning D., van Rossum D.B., Patterson R.L., Snyder S.H. A peptide inhibitor of cytochrome c/inositol 1,4,5-trisphosphate receptor binding blocks intrinsic and extrinsic cell death pathways. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:1466-1471.
45. Elkoreh G., Blais V., Beliveau E., Guillemette G., Denault J.B. Type 1 inositol-1,4,5-trisphosphate receptor is a late substrate of caspases during apoptosis. J. Cell. Biochem. 2012, 113:2775-2784.
46. Akimzhanov A.M., Barral J.M., Boehning D. Caspase 3 cleavage of the inositol 1,4,5-trisphosphate receptor does not contribute to apoptotic calcium release. Cell Calcium 2012, 10.1016/j.ceca.2012.10.002.
47. 2+ homeostasis. J. Biol. Chem. 2011, 286:35998-36010.
48. 2+ signaling and apoptosis by the BH4 domain of Bcl-2 versus Bcl-Xl. Cell Death Differ. 2012, 19:295-309.
49. 3 through gap junctions is critical, but not sufficient, for the spread of apoptosis. Cell Death Differ. 2012, 19:947-957.
50. 2+-entry pathway. J. Biol. Chem. 2012, 287:12250-12266.
51. Zhang S., Hisatsune C., Matsu-Ura T., Mikoshiba K. G-protein-coupled receptor kinase-interacting proteins inhibit apoptosis by inositol 1,4,5-triphosphate receptor-mediated Ca2+ signal regulation. J. Biol. Chem. 2009, 284:29158-29169.
52. 2+ channel activity in the endoplasmic reticulum. J. Biol. Chem. 2008, 283:15946-15955.
53. 2+-permeable channel pore. J. Biol. Chem. 2012, 287:2544-2557.
54. Chae H.J., Kim H.R., Xu C., Bailly-Maitre B., Krajewska M., Krajewski S., Banares S., Cui J., Digicaylioglu M., Ke N., Kitada S., Monosov E., Thomas M., Kress C.L., Babendure J.R., Tsien R.Y., Lipton S.A., Reed J.C. BI-1 regulates an apoptosis pathway linked to endoplasmic reticulum stress. Mol. Cell 2004, 15:355-366.
55. Rimessi A., Marchi S., Fotino C., Romagnoli A., Huebner K., Croce C.M., Pinton P., Rizzuto R. Intramitochondrial calcium regulation by the FHIT gene product sensitizes to apoptosis. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:12753-12758.
56. Monteith G.R., Davis F.M., Roberts-Thomson S.J. Calcium channels and pumps in cancer: changes and consequences. J. Biol. Chem. 2012, 287:31666-31673.
57. Arbabian A., Brouland J.P., Gelebart P., Kovacs T., Bobe R., Enouf J., Papp B. Endoplasmic reticulum calcium pumps and cancer. Biofactors 2011, 37:139-149.
58. Prevarskaya N., Skryma R., Shuba Y. Calcium in tumour metastasis: new roles for known actors. Nat. Rev. Cancer 2011, 11:609-618.
59. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
60. 2+ signalling is involved in estradiol-induced breast cancer epithelial cell growth. Mol. Cancer 2010, 9:156.
61. Shibao K., Fiedler M.J., Nagata J., Minagawa N., Hirata K., Nakayama Y., Iwakiri Y., Nathanson M.H., Yamaguchi K. The type III inositol 1,4,5-trisphosphate receptor is associated with aggressiveness of colorectal carcinoma. Cell Calcium 2010, 48:315-323.
62. Kang S.S., Han K.S., Ku B.M., Lee Y.K., Hong J., Shin H.Y., Almonte A.G., Woo D.H., Brat D.J., Hwang E.M., Yoo S.H., Chung C.K., Park S.H., Paek S.H., Roh E.J., Lee S.J., Park J.Y., Traynelis S.F., Lee C.J. Caffeine-mediated inhibition of calcium release channel inositol 1,4,5-trisphosphate receptor subtype 3 blocks glioblastoma invasion and extends survival. Cancer Res. 2010, 70:1173-1183.
63. 3R1) modulates the acquisition of cisplatin resistance in bladder cancer cell lines. Oncogene 2005, 24:1396-1402.
64. Boehmerle W., Splittgerber U., Lazarus M.B., McKenzie K.M., Johnston D.G., Austin D.J., Ehrlich B.E. Paclitaxel induces calcium oscillations via an inositol 1,4,5-trisphosphate receptor and neuronal calcium sensor 1-dependent mechanism. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:18356-18361.
65. Fujimoto T., Machida T., Tanaka Y., Tsunoda T., Doi K., Ota T., Okamura T., Kuroki M., Shirasawa S. KRAS-induced actin-interacting protein is required for the proper localization of inositol 1,4,5-trisphosphate receptor in the epithelial cells. Biochem. Biophys. Res. Commun. 2011, 407:438-443.
66. Stephens L., Anderson K., Stokoe D., Erdjument-Bromage H., Painter G.F., Holmes A.B., Gaffney P.R., Reese C.B., McCormick F., Tempst P., Coadwell J., Hawkins P.T. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science 1998, 279:710-714.
67. Downward J. PI 3-kinase, Akt and cell survival. Semin. Cell Dev. Biol. 2004, 15:177-182.
68. Blanco-Aparicio C., Renner O., Leal J.F., Carnero A. PTEN, more than the AKT pathway. Carcinogenesis 2007, 28:1379-1386.
69. Chan T.O., Tsichlis P.N. PDK2: a complex tail in one Akt. Sci. STKE 2001, 2001:e1.
70. Hers I., Vincent E.E., Tavare J.M. Akt signalling in health and disease. Cell. Signal. 2011, 23:1515-1527.
71. Dahia P.L. PTEN, a unique tumor suppressor gene. Endocr. Relat. Cancer 2000, 7:115-129.
72. Song M.S., Salmena L., Pandolfi P.P. The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol. 2012, 13:283-296.
73. Parsons D.W., Wang T.L., Samuels Y., Bardelli A., Cummins J.M., DeLong L., Silliman N., Ptak J., Szabo S., Willson J.K., Markowitz S., Kinzler K.W., Vogelstein B., Lengauer C., Velculescu V.E. Colorectal cancer: mutations in a signalling pathway. Nature 2005, 436:792.
74. Samuels Y., Ericson K. Oncogenic PI3K and its role in cancer. Curr. Opin. Oncol. 2006, 18:77-82.
75. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2:489-501.
76. Carnero A. The PKB/AKT pathway in cancer. Curr. Pharm. Des. 2010, 16:34-44.
77. Zhang X., Tang N., Hadden T.J., Rishi A.K. Akt, FoxO and regulation of apoptosis. Biochim. Biophys. Acta 2011, 1813:1978-1986.
78. Dansen T.B., Burgering B.M. Unravelling the tumor-suppressive functions of FOXO proteins. Trends Cell Biol. 2008, 18:421-429.
79. Oren M. Decision making by p53: life, death and cancer. Cell Death Differ. 2003, 10:431-442.
80. Meulmeester E., Jochemsen A.G. p53: a guide to apoptosis. Curr. Cancer Drug Targets 2008, 8:87-97.
81. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., Gazdar A., Powell S.M., Riggins G.J., Willson J.K., Markowitz S., Kinzler K.W., Vogelstein B., Velculescu V.E. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304:554.
82. Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012, 149:274-293.
83. Floor S.L., Dumont J.E., Maenhaut C., Raspe E. Hallmarks of cancer: of all cancer cells, all the time?. Trends Mol. Med. 2012, 18:509-515.
84. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., Lane H., Hofmann F., Hicklin D.J., Ludwig D.L., Baselga J., Rosen N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66:1500-1508.
85. Khan M.T., Wagner L., Yule D.I., Bhanumathy C., Joseph S.K. Akt kinase phosphorylation of inositol 1,4,5-trisphosphate receptors. J. Biol. Chem. 2006, 281:3731-3737.
86. Szado T., Vanderheyden V., Parys J.B., De Smedt H., Rietdorf K., Kotelevets L., Chastre E., Khan F., Landegren U., Soderberg O., Bootman M.D., Roderick H.L. Phosphorylation of inositol 1,4,5-trisphosphate receptors by protein kinase B/Akt inhibits Ca2+ release and apoptosis. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:2427-2432.
87. 2+-dependent apoptotic stimuli. Biochem. Biophys. Res. Commun. 2008, 375:501-505.
88. Haas-Kogan D., Shalev N., Wong M., Mills G., Yount G., Stokoe D. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr. Biol. 1998, 8:1195-1198.
89. Blackshaw S., Sawa A., Sharp A.H., Ross C.A., Snyder S.H., Khan A.A. Type 3 inositol 1,4,5-trisphosphate receptor modulates cell death. FASEB J. 2000, 14:1375-1379.
90. 2+ signals into mitochondria. J. Biol. Chem. 2005, 280:40892-40900.
91. Anyatonwu G., Khan M.T., Schug Z.T., da Fonseca P.C., Morris E.P., Joseph S.K. Calcium-dependent conformational changes in inositol trisphosphate receptors. J. Biol. Chem. 2010, 285:25085-25093.
92. Schug Z.T., Joseph S.K. The role of the S4-S5 linker and C-terminal tail in inositol 1,4,5-trisphosphate receptor function. J. Biol. Chem. 2006, 281:24431-24440.
93. 2+ channel, is a novel substrate of polo-like kinase 1 in eggs. Dev. Biol. 2008, 320:402-413.
94. Vanderheyden V., Wakai T., Bultynck G., De Smedt H., Parys J.B., Fissore R.A. Regulation of inositol 1,4,5-trisphosphate receptor type 1 function during oocyte maturation by MPM-2 phosphorylation. Cell Calcium 2009, 46:56-64.
95. Tang T.S., Tu H., Wang Z., Bezprozvanny I. Modulation of type 1 inositol (1,4,5)-trisphosphate receptor function by protein kinase a and protein phosphatase 1alpha. J. Neurosci. 2003, 23:403-415.
96. 3-induced calcium release activity. J. Biol. Chem. 2009, 284:372-380.
97. Fukatsu K., Bannai H., Inoue T., Mikoshiba K. 4.1N binding regions of inositol 1,4,5-trisphosphate receptor type 1. Biochem. Biophys. Res. Commun. 2006, 342:573-576.
98. Tang T.S., Tu H., Chan E.Y., Maximov A., Wang Z., Wellington C.L., Hayden M.R., Bezprozvanny I. Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron 2003, 39:227-239.
99. Foskett J.K., White C., Cheung K.H., Mak D.O. Inositol trisphosphate receptor Ca2+ release channels. Physiol. Rev. 2007, 87:593-658.
100. Parys J.B., De Smedt H. Inositol 1,4,5-trisphosphate and its receptors. Adv. Exp. Med. Biol. 2012, 740:255-279.
101. Hagar R.E., Burgstahler A.D., Nathanson M.H., Ehrlich B.E. Type III InsP3 receptor channel stays open in the presence of increased calcium. Nature 1998, 396:81-84.
102. Bezprozvanny I., Watras J., Ehrlich B.E. Bell-shaped calcium-response curves of Ins(1,4,5)P3- and calcium-gated channels from endoplasmic reticulum of cerebellum. Nature 1991, 351:751-754.
103. 2+. Biochem. J. 1995, 306(Pt 2):445-451.
104. 2+ release in A7r5 smooth-muscle cells and in EBTr cells from tracheal mucosa. Biochem. Biophys. Res. Commun. 1997, 237:354-358.
105. 3 receptor in 16HBE14o- bronchial mucosal cells. J. Biol. Chem. 1998, 273:8983-8986.
106. Fregeau M.O., Regimbald-Dumas Y., Guillemette G. Positive regulation of inositol 1,4,5-trisphosphate-induced Ca2+ release by mammalian target of rapamycin (mTOR) in RINm5F cells. J. Cell. Biochem. 2011, 112:723-733.
107. Brunelle J.K., Letai A. Control of mitochondrial apoptosis by the Bcl-2 family. J. Cell Sci. 2009, 122:437-441.
108. Chipuk J.E., Moldoveanu T., Llambi F., Parsons M.J., Green D.R. The BCL-2 family reunion. Mol. Cell 2010, 37:299-310.
109. Tsujimoto Y., Jaffe E., Cossman J., Gorham J., Nowell P.C., Croce C.M. Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the t(11;14) chromosome translocation. Nature 1985, 315:340-343.
110. Aisenberg A.C., Wilkes B.M., Jacobson J.O. The bcl-2 gene is rearranged in many diffuse B-cell lymphomas. Blood 1988, 71:969-972.
111. Raghoebier S., van Krieken J.H., Kluin-Nelemans J.C., Gillis A., van Ommen G.J., Ginsberg A.M., Raffeld M., Kluin P.M. Oncogene rearrangements in chronic B-cell leukemia. Blood 1991, 77:1560-1564.
112. Dyer M.J., Zani V.J., Lu W.Z., O'Byrne A., Mould S., Chapman R., Heward J.M., Kayano H., Jadayel D., Matutes E., et al. BCL2 translocations in leukemias of mature B cells. Blood 1994, 83:3682-3688.
113. Dighiero G., Binet J.L. Chronic lymphocytic leukemia. Hematol. Cell Ther. 1996, 38(Suppl. 2):S41-S61.
114. Adachi M., Cossman J., Longo D., Croce C.M., Tsujimoto Y. Variant translocation of the bcl-2 gene to immunoglobulin lambda light chain gene in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. 1989, 86:2771-2774.
115. Calin G.A., Ferracin M., Cimmino A., Di Leva G., Shimizu M., Wojcik S.E., Iorio M.V., Visone R., Sever N.I., Fabbri M., Iuliano R., Palumbo T., Pichiorri F., Roldo C., Garzon R., Sevignani C., Rassenti L., Alder H., Volinia S., Liu C.G., Kipps T.J., Negrini M., Croce C.M. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N. Engl. J. Med. 2005, 353:1793-1801.
116. Carney D.A., Wierda W.G. Genetics and molecular biology of chronic lymphocytic leukemia. Curr. Treat. Options Oncol. 2005, 6:215-225.
117. Calin G.A., Pekarsky Y., Croce C.M. The role of microRNA and other non-coding RNA in the pathogenesis of chronic lymphocytic leukemia. Best Pract. Res. Clin. Haematol. 2007, 20:425-437.
118. Kelly P.N., Strasser A. The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ. 2011, 18:1414-1424.
119. Chresta C.M., Arriola E.L., Hickman J.A. Apoptosis and cancer chemotherapy. Behring Inst. Mitt. 1996, 232-240.
120. Daniel J.C., Smythe W.R. The role of Bcl-2 family members in non-small cell lung cancer. Semin. Thorac. Cardiovasc. Surg. 2004, 16:19-27.
121. Letai A.G. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat. Rev. Cancer 2008, 8:121-132.
122. Arbel N., Shoshan-Barmatz V. Voltage-dependent anion channel 1-based peptides interact with Bcl-2 to prevent antiapoptotic activity. J. Biol. Chem. 2010, 285:6053-6062.
123. 2+ signals to mitochondria. Cell Death Differ. 2012, 19:267-273.
124. 2+ fluxes. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:6569-6573.
125. Distelhorst C.W., Lam M., McCormick T.S. Bcl-2 inhibits hydrogen peroxide-induced ER Ca2+ pool depletion. Oncogene 1996, 12:2051-2055.
126. Breckenridge D.G., Germain M., Mathai J.P., Nguyen M., Shore G.C. Regulation of apoptosis by endoplasmic reticulum pathways. Oncogene 2003, 22:8608-8618.
127. Distelhorst C.W., Shore G.C. Bcl-2 and calcium: controversy beneath the surface. Oncogene 2004, 23:2875-2880.
128. 2+ influx in Bcl-2-overexpressing cells. J. Cell Biol. 2000, 148:857-862.
129. Pinton P., Ferrari D., Rapizzi E., Di Virgilio F., Pozzan T., Rizzuto R. The Ca2+ concentration of the endoplasmic reticulum is a key determinant of ceramide-induced apoptosis: significance for the molecular mechanism of Bcl-2 action. EMBO J. 2001, 20:2690-2701.
130. 2+: a control point for apoptosis. Science 2003, 300:135-139.
131. Palmer A.E., Jin C., Reed J.C., Tsien R.Y. Bcl-2-mediated alterations in endoplasmic reticulum Ca2+ analyzed with an improved genetically encoded fluorescent sensor. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:17404-17409.
132. Oakes S.A., Scorrano L., Opferman J.T., Bassik M.C., Nishino M., Pozzan T., Korsmeyer S.J. Proapoptotic BAX and BAK regulate the type 1 inositol trisphosphate receptor and calcium leak from the endoplasmic reticulum. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:105-110.
133. Li C., Wang X., Vais H., Thompson C.B., Foskett J.K., White C. Apoptosis regulation by Bcl-x(L) modulation of mammalian inositol 1,4,5-trisphosphate receptor channel isoform gating. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:12565-12570.
134. 2+ homeostasis downstream of Bcl-2 family proteins. J. Biol. Chem. 2008, 283:11477-11484.
135. Rojas-Rivera D., Caballero B., Zamorano S., Lisbona F., Hetz C. Alternative functions of the BCL-2 protein family at the endoplasmic reticulum. Adv. Exp. Med. Biol. 2010, 687:33-47.
136. Lust S., Vanhoecke B., Van Gele M., Boelens J., Van Melckebeke H., Kaileh M., Vanden Berghe W., Haegeman G., Philippe J., Bracke M., Offner F. Xanthohumol activates the proapoptotic arm of the unfolded protein response in chronic lymphocytic leukemia. Anticancer Res. 2009, 29:3797-3805.
137. Boelens J., Jais J.P., Vanhoecke B., Beck I., Van Melckebeke H., Philippe J., Bracke M., Jardin F., Briere J., Leroy K., Offner F., Lust S. ER stress in diffuse large B cell lymphoma: GRP94 is a possible biomarker in germinal center versus activated B-cell type. Leuk. Res. 2012, 37:3-8.
138. Chen R., Valencia I., Zhong F., McColl K.S., Roderick H.L., Bootman M.D., Berridge M.J., Conway S.J., Holmes A.B., Mignery G.A., Velez P., Distelhorst C.W. Bcl-2 functionally interacts with inositol 1,4,5-trisphosphate receptors to regulate calcium release from the ER in response to inositol 1,4,5-trisphosphate. J. Cell Biol. 2004, 166:193-203.
139. Zhong F., Davis M.C., McColl K.S., Distelhorst C.W. Bcl-2 differentially regulates Ca2+ signals according to the strength of T cell receptor activation. J. Cell Biol. 2006, 172:127-137.
140. Rong Y.P., Aromolaran A.S., Bultynck G., Zhong F., Li X., McColl K., Matsuyama S., Herlitze S., Roderick H.L., Bootman M.D., Mignery G.A., Parys J.B., De Smedt H., Distelhorst C.W. Targeting Bcl-2-IP3 receptor interaction to reverse Bcl-2's inhibition of apoptotic calcium signals. Mol. Cell 2008, 31:255-265.
141. 2+ uptake by mitochondria without affecting ER calcium store content. Cell Calcium 2008, 44:324-338.
142. 2+ signaling and disease. Cell Calcium 2011, 50:234-241.
143. Rong Y.P., Bultynck G., Aromolaran A.S., Zhong F., Parys J.B., De Smedt H., Mignery G.A., Roderick H.L., Bootman M.D., Distelhorst C.W. The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domain of the IP3 receptor. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:14397-14402.
144. 3 receptor interaction. Blood 2011, 117:2924-2934.
145. Certo M., Del Gaizo Moore V., Nishino M., Wei G., Korsmeyer S., Armstrong S.A., Letai A. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006, 9:351-365.
146. Del Gaizo Moore V., Brown J.R., Certo M., Love T.M., Novina C.D., Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J. Clin. Invest. 2007, 117:112-121.
147. Deng J., Carlson N., Takeyama K., Dal Cin P., Shipp M., Letai A. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 2007, 12:171-185.
148. Ni Chonghaile T., Sarosiek K.A., Vo T.T., Ryan J.A., Tammareddi A., Moore Vdel G., Deng J., Anderson K.C., Richardson P., Tai Y.T., Mitsiades C.S., Matulonis U.A., Drapkin R., Stone R., Deangelo D.J., McConkey D.J., Sallan S.E., Silverman L., Hirsch M.S., Carrasco D.R., Letai A. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 2011, 334:1129-1133.
149. Rong Y., Distelhorst C.W. Bcl-2 protein family members: versatile regulators of calcium signaling in cell survival and apoptosis. Annu. Rev. Physiol. 2008, 70:73-91.
150. Rodriguez D., Rojas-Rivera D., Hetz C. Integrating stress signals at the endoplasmic reticulum: The BCL-2 protein family rheostat. Biochim. Biophys. Acta 2011, 1813:564-574.
151. Xerri L., Hassoun J., Devilard E., Birnbaum D., Birg F. BCL-X and the apoptotic machinery of lymphoma cells. Leuk. Lymphoma 1998, 28:451-458.
152. Benyamini H., Friedler A. The ASPP interaction network: electrostatic differentiation between pro- and anti-apoptotic proteins. J. Mol. Recognit. 2011, 24:266-274.
153. Kampa K.M., Bonin M., Lopez C.D. New insights into the expanding complexity of the tumor suppressor ASPP2. Cell Cycle 2009, 8:2871-2876.
154. Katz C., Benyamini H., Rotem S., Lebendiker M., Danieli T., Iosub A., Refaely H., Dines M., Bronner V., Bravman T., Shalev D.E., Rudiger S., Friedler A. Molecular basis of the interaction between the antiapoptotic Bcl-2 family proteins and the proapoptotic protein ASPP2. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:12277-12282.
155. Monaco G., Vervliet T., Akl H., Bultynck G. The selective BH4-domain biology of Bcl-2-family members: IP 3 Rs and beyond. Cell. Mol. Life Sci. 2012, 1-13.
156. Ahn J., Byeon I.J., Byeon C.H., Gronenborn A.M. Insight into the structural basis of pro- and antiapoptotic p53 modulation by ASPP proteins. J. Biol. Chem. 2009, 284:13812-13822.
157. Sullivan A., Lu X. ASPP: a new family of oncogenes and tumour suppressor genes. Br. J. Cancer 2007, 96:196-200.
158. Vives V., Slee E.A., Lu X. ASPP2: a gene that controls life and death in vivo. Cell Cycle 2006, 5:2187-2190.
159. 2+ signaling. J. Biol. Chem. 2010, 285:13678-13684.
160. 2+ release channel BH3 domains. Biophys. J. 2009, 96:391a.
161. 2+ homeostasis by altering expression of inositol 1,4,5-trisphosphate receptors. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:9830-9835.
162. Arbel N., Ben-Hail D., Shoshan-Barmatz V. Mediation of the antiapoptotic activity of Bcl-xL protein upon interaction with VDAC1 protein. J. Biol. Chem. 2012, 287:23152-23161.
163. 2+ homeostasis. Mol. Biol. Cell 2012, 23:2605-2618.
164. Chen L., Willis S.N., Wei A., Smith B.J., Fletcher J.I., Hinds M.G., Colman P.M., Day C.L., Adams J.M., Huang D.C. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol. Cell 2005, 17:393-403.
165. Derenne S., Monia B., Dean N.M., Taylor J.K., Rapp M.J., Harousseau J.L., Bataille R., Amiot M. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 2002, 100:194-199.
166. Rassidakis G.Z., Lai R., McDonnell T.J., Cabanillas F., Sarris A.H., Medeiros L.J. Overexpression of Mcl-1 in anaplastic large cell lymphoma cell lines and tumors. Am. J. Pathol. 2002, 160:2309-2310.
167. Cho-Vega J.H., Rassidakis G.Z., Admirand J.H., Oyarzo M., Ramalingam P., Paraguya A., McDonnell T.J., Amin H.M., Medeiros L.J. MCL-1 expression in B-cell non-Hodgkin's lymphomas. Hum. Pathol. 2004, 35:1095-1100.
168. Aichberger K.J., Mayerhofer M., Krauth M.T., Skvara H., Florian S., Sonneck K., Akgul C., Derdak S., Pickl W.F., Wacheck V., Selzer E., Monia B.P., Moriggl R., Valent P., Sillaber C. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 2005, 105:3303-3311.
169. Sieghart W., Losert D., Strommer S., Cejka D., Schmid K., Rasoul-Rockenschaub S., Bodingbauer M., Crevenna R., Monia B.P., Peck-Radosavljevic M., Wacheck V. Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. J. Hepatol. 2006, 44:151-157.
170. Akgul C. Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell. Mol. Life Sci. 2009, 66:1326-1336.
171. Varadarajan S., Bampton E.T., Smalley J.L., Tanaka K., Caves R.E., Butterworth M., Wei J., Pellecchia M., Mitcheson J., Gant T.W., Dinsdale D., Cohen G.M. A novel cellular stress response characterised by a rapid reorganisation of membranes of the endoplasmic reticulum. Cell Death Differ. 2012, 19:1896-1907.
172. Urra H., Hetz C. The ER in 4D: a novel stress pathway controlling endoplasmic reticulum membrane remodeling. Cell Death Differ. 2012, 19:1893-1895.
173. 2+-signaling complexes and Ca2+ regulation in secretory and muscle cells from PERK-knockout mice. J. Cell Sci. 2006, 119:153-161.
174. Xu Q., Reed J.C. Bax inhibitor-1, a mammalian apoptosis suppressor identified by functional screening in yeast. Mol. Cell 1998, 1:337-346.
175. Reimers K., Choi C.Y., Bucan V., Vogt P.M. The Bax Inhibitor-1 (BI-1) family in apoptosis and tumorigenesis. Curr. Mol. Med. 2008, 8:148-156.
176. Robinson K.S., Clements A., Williams A.C., Berger C.N., Frankel G. Bax inhibitor 1 in apoptosis and disease. Oncogene 2011, 30:2391-2400.
177. Schmits R., Cochlovius B., Treitz G., Regitz E., Ketter R., Preuss K.D., Romeike B.F., Pfreundschuh M. Analysis of the antibody repertoire of astrocytoma patients against antigens expressed by gliomas. Int. J. Cancer 2002, 98:73-77.
178. Grzmil M., Thelen P., Hemmerlein B., Schweyer S., Voigt S., Mury D., Burfeind P. Bax inhibitor-1 is overexpressed in prostate cancer and its specific down-regulation by RNA interference leads to cell death in human prostate carcinoma cells. Am. J. Pathol. 2003, 163:543-552.
179. Grzmil M., Kaulfuss S., Thelen P., Hemmerlein B., Schweyer S., Obenauer S., Kang T.W., Burfeind P. Expression and functional analysis of Bax inhibitor-1 in human breast cancer cells. J. Pathol. 2006, 208:340-349.
180. Tanaka R., Ishiyama T., Uchihara T., Inadome Y., Iijima T., Morishita Y., Kano J., Goya T., Noguchi M. Expression of the Bax inhibitor-1 gene in pulmonary adenocarcinoma. Cancer 2006, 106:648-653.
181. Anderson P.W., Tennant B.C., Lee Z. Cross-species hybridization of woodchuck hepatitis virus-induced hepatocellular carcinoma using human oligonucleotide microarrays. World J. Gastroenterol. 2006, 12:4646-4651.
182. Zhang M., Li X., Zhang Y., Zhou K. Bax inhibitor-1 mediates apoptosis-resistance in human nasopharyngeal carcinoma cells. Mol. Cell. Biochem. 2010, 333:1-7.
183. Lee G.H., Yan C., Shin S.J., Hong S.C., Ahn T., Moon A., Park S.J., Lee Y.C., Yoo W.H., Kim H.T., Kim D.S., Chae S.W., Kim H.R., Chae H.J. BAX inhibitor-1 enhances cancer metastasis by altering glucose metabolism and activating the sodium-hydrogen exchanger: the alteration of mitochondrial function. Oncogene 2010, 29:2130-2141.
184. Lee G.H., Hwang J.D., Choi J.Y., Park H.J., Cho J.Y., Kim K.W., Chae H.J., Kim H.R. An acidic pH environment increases cell death and pro-inflammatory cytokine release in osteoblasts: the involvement of BAX inhibitor-1. Int. J. Biochem. Cell Biol. 2011, 43:1305-1317.
185. Lee G.H., Ahn T., Kim D.S., Park S.J., Lee Y.C., Yoo W.H., Jung S.J., Yang J.S., Kim S., Muhlrad A., Seo Y.R., Chae S.W., Kim H.R., Chae H.J. Bax inhibitor 1 increases cell adhesion through actin polymerization: involvement of calcium and actin binding. Mol. Cell. Biol. 2010, 30:1800-1813.
186. Henke N., Lisak D.A., Schneider L., Habicht J., Pergande M., Methner A. The ancient cell death suppressor BAX inhibitor-1. Cell Calcium 2011, 50:251-260.
187. Kiviluoto S., Schneider L., Luyten T., Vervliet T., Missiaen L., De Smedt H., Parys J., Methner A., Bultynck G. Bax Inhibitor-1 is a novel IP3 receptor-interacting and -sensitizing protein. Cell Death Dis. 2012, 3:e367.
188. 2+-mediated bioenergetics to promote autophagy. Genes Dev. 2012, 26:1041-1054.
189. Guo J.Y., Chen H.Y., Mathew R., Fan J., Strohecker A.M., Karsli-Uzunbas G., Kamphorst J.J., Chen G., Lemons J.M., Karantza V., Coller H.A., Dipaola R.S., Gelinas C., Rabinowitz J.D., White E. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev. 2011, 25:460-470.
190. Fujimoto T., Machida T., Tsunoda T., Doi K., Ota T., Kuroki M., Shirasawa S. KRAS-induced actin-interacting protein regulates inositol 1,4,5-trisphosphate-receptor-mediated calcium release. Biochem. Biophys. Res. Commun. 2011, 408:214-217.
191. Castillo K., Rojas-Rivera D., Lisbona F., Caballero B., Nassif M., Court F.A., Schuck S., Ibar C., Walter P., Sierralta J., Glavic A., Hetz C. BAX inhibitor-1 regulates autophagy by controlling the IRE1alpha branch of the unfolded protein response. EMBO J. 2011, 30:4465-4478.
192. Lisbona F., Rojas-Rivera D., Thielen P., Zamorano S., Todd D., Martinon F., Glavic A., Kress C., Lin J.H., Walter P., Reed J.C., Glimcher L.H., Hetz C. BAX inhibitor-1 is a negative regulator of the ER stress sensor IRE1alpha. Mol. Cell 2009, 33:679-691.
193. Inokuchi J., Komiya M., Baba I., Naito S., Sasazuki T., Shirasawa S. Deregulated expression of KRAP, a novel gene encoding actin-interacting protein, in human colon cancer cells. J. Hum. Genet. 2004, 49:46-52.
194. Fujimoto T., Koyanagi M., Baba I., Nakabayashi K., Kato N., Sasazuki T., Shirasawa S. Analysis of KRAP expression and localization, and genes regulated by KRAP in a human colon cancer cell line. J. Hum. Genet. 2007, 52:978-984.
195. Fujimoto T., Miyasaka K., Koyanagi M., Tsunoda T., Baba I., Doi K., Ohta M., Kato N., Sasazuki T., Shirasawa S. Altered energy homeostasis and resistance to diet-induced obesity in KRAP-deficient mice. PLoS One 2009, 4:e4240.
196. Dingli F., Parys J.B., Loew D., Saule S., Mery L. Vimentin and the K-Ras-induced actin-binding protein control inositol-(1,4,5)-trisphosphate receptor redistribution during MDCK cell differentiation. J. Cell Sci. 2012, 10.3892/ijmm.2012.1126.
197. 3R in the stomach and kidney. Int. J. Mol. Med. 2012, 30:1287-1293.
198. Fujimoto T., Machida T., Tsunoda T., Doi K., Ota T., Kuroki M., Shirasawa S. Determination of the critical region of KRAS-induced actin-interacting protein for the interaction with inositol 1,4,5-trisphosphate receptor. Biochem. Biophys. Res. Commun. 2011, 408:282-286.
199. Fujimoto T., Shirasawa S. KRAS-induced actin-interacting protein: a potent target for obesity, diabetes and cancer. Anticancer Res. 2011, 31:2413-2417.
200. Satelli A., Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell. Mol. Life Sci. 2011, 68:3033-3046.
201. Salomoni P., Pandolfi P.P. The role of PML in tumor suppression. Cell 2002, 108:165-170.
202. Salomoni P., Ferguson B.J., Wyllie A.H., Rich T. New insights into the role of PML in tumour suppression. Cell Res. 2008, 18:622-640.
203. Pinton P., Giorgi C., Pandolfi P.P. The role of PML in the control of apoptotic cell fate: a new key player at ER-mitochondria sites. Cell Death Differ. 2011, 18:1450-1456.
204. Bernardi R., Pandolfi P.P. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat. Rev. Mol. Cell Biol. 2007, 8:1006-1016.
205. Bernardi R., Papa A., Pandolfi P.P. Regulation of apoptosis by PML and the PML-NBs. Oncogene 2008, 27:6299-6312.
206. Wang Z.G., Ruggero D., Ronchetti S., Zhong S., Gaboli M., Rivi R., Pandolfi P.P. PML is essential for multiple apoptotic pathways. Nat. Genet. 1998, 20:266-272.
207. Rego E.M., Wang Z.G., Peruzzi D., He L.Z., Cordon-Cardo C., Pandolfi P.P. Role of promyelocytic leukemia (PML) protein in tumor suppression. J. Exp. Med. 2001, 193:521-529.
208. Trotman L.C., Alimonti A., Scaglioni P.P., Koutcher J.A., Cordon-Cardo C., Pandolfi P.P. Identification of a tumour suppressor network opposing nuclear Akt function. Nature 2006, 441:523-527.
209. Giorgi C., Ito K., Lin H.K., Santangelo C., Wieckowski M.R., Lebiedzinska M., Bononi A., Bonora M., Duszynski J., Bernardi R., Rizzuto R., Tacchetti C., Pinton P., Pandolfi P.P. PML regulates apoptosis at endoplasmic reticulum by modulating calcium release. Science 2010, 330:1247-1251.
210. Miyakawa T., Maeda A., Yamazawa T., Hirose K., Kurosaki T., Iino M. Encoding of Ca2+ signals by differential expression of IP3 receptor subtypes. EMBO J. 1999, 18:1303-1308.
211. Scupoli M.T., Pizzolo G. Signaling pathways activated by the B-cell receptor in chronic lymphocytic leukemia. Expert Rev. Hematol. 2012, 5:341-348.
212. Woyach J.A., Johnson A.J., Byrd J.C. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 2012, 120:1175-1184.
213. Sinha S., Levine B. The autophagy effector Beclin 1: a novel BH3-only protein. Oncogene 2008, 27(Suppl. 1):S137-S148.
214. Klionsky D.J., Baehrecke E.H., Brumell J.H., Chu C.T., Codogno P., Cuervo A.M., Debnath J., Deretic V., Elazar Z., Eskelinen E.L., Finkbeiner S., Fueyo-Margareto J., Gewirtz D., Jaattela M., Kroemer G., Levine B., Melia T.J., Mizushima N., Rubinsztein D.C., Simonsen A., Thorburn A., Thumm M., Tooze S.A. A comprehensive glossary of autophagy-related molecules and processes (2nd edition). Autophagy 2011, 7:1273-1294.
215. Kang R., Zeh H.J., Lotze M.T., Tang D. The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ. 2011, 18:571-580.
216. Zalckvar E., Berissi H., Mizrachy L., Idelchuk Y., Koren I., Eisenstein M., Sabanay H., Pinkas-Kramarski R., Kimchi A. DAP-kinase-mediated phosphorylation on the BH3 domain of beclin 1 promotes dissociation of beclin 1 from Bcl-XL and induction of autophagy. EMBO Rep. 2009, 10:285-292.
217. Zalckvar E., Berissi H., Eisenstein M., Kimchi A. Phosphorylation of Beclin 1 by DAP-kinase promotes autophagy by weakening its interactions with Bcl-2 and Bcl-XL. Autophagy 2009, 5:720-722.
218. Bialik S., Kimchi A. Lethal weapons: DAP-kinase, autophagy and cell death: DAP-kinase regulates autophagy. Curr. Opin. Cell Biol. 2010, 22:199-205.
219. Wei Y., Pattingre S., Sinha S., Bassik M., Levine B. JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy. Mol. Cell 2008, 30:678-688.
220. Pattingre S., Bauvy C., Carpentier S., Levade T., Levine B., Codogno P. Role of JNK1-dependent Bcl-2 phosphorylation in ceramide-induced macroautophagy. J. Biol. Chem. 2009, 284:2719-2728.
221. Lorin S., Pierron G., Ryan K.M., Codogno P., Djavaheri-Mergny M. Evidence for the interplay between JNK and p53-DRAM signalling pathways in the regulation of autophagy. Autophagy 2010, 6:153-154.
222. Wang R.C., Wei Y., An Z., Zou Z., Xiao G., Bhagat G., White M., Reichelt J., Levine B. Akt-mediated regulation of autophagy and tumorigenesis through beclin 1 phosphorylation. Science 2012, 338:956-959.
223. Koren I., Kimchi A. Promoting tumorigenesis by suppressing autophagy. Science 2012, 338:889-890.
224. He C., Levine B. The Beclin 1 interactome. Curr. Opin. Cell Biol. 2010, 22:140-149.
225. Decuypere J.P., Parys J.B., Bultynck G. Regulation of the autophagic Bcl-2/Beclin 1 interaction. Cells 2012, 1:284-312.
226. Liang X.H., Jackson S., Seaman M., Brown K., Kempkes B., Hibshoosh H., Levine B. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 1999, 402:672-676.
227. Gozuacik D., Kimchi A. Autophagy as a cell death and tumor suppressor mechanism. Oncogene 2004, 23:2891-2906.
228. Qu X., Yu J., Bhagat G., Furuya N., Hibshoosh H., Troxel A., Rosen J., Eskelinen E.L., Mizushima N., Ohsumi Y., Cattoretti G., Levine B. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J. Clin. Invest. 2003, 112:1809-1820.
229. Yue Z., Jin S., Yang C., Levine A.J., Heintz N. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:15077-15082.
230. White E. Deconvoluting the context-dependent role for autophagy in cancer. Nat. Rev. Cancer 2012, 12:401-410.
231. Mathew R., White E. Autophagy in tumorigenesis and energy metabolism: friend by day, foe by night. Curr. Opin. Genet. Dev. 2011, 21:113-119.
232. Aita V.M., Liang X.H., Murty V.V., Pincus D.L., Yu W., Cayanis E., Kalachikov S., Gilliam T.C., Levine B. Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21. Genomics 1999, 59:59-65.
233. Morselli E., Galluzzi L., Kepp O., Vicencio J.M., Criollo A., Maiuri M.C., Kroemer G. Anti- and pro-tumor functions of autophagy. Biochim. Biophys. Acta 2009, 1793:1524-1532.
234. Vicencio J.M., Ortiz C., Criollo A., Jones A.W., Kepp O., Galluzzi L., Joza N., Vitale I., Morselli E., Tailler M., Castedo M., Maiuri M.C., Molgo J., Szabadkai G., Lavandero S., Kroemer G. The inositol 1,4,5-trisphosphate receptor regulates autophagy through its interaction with Beclin 1. Cell Death Differ. 2009, 16:1006-1017.
235. Decuypere J.P., Welkenhuyzen K., Luyten T., Ponsaerts R., Dewaele M., Molgo J., Agostinis P., Missiaen L., De Smedt H., Parys J.B., Bultynck G. IP 3 receptor-mediated Ca (2+) signaling and autophagy induction are interrelated. Autophagy 2011, 7.
236. 2+ in autophagy regulation. Cell Calcium 2011, 50:242-250.
237. 3 receptors, mitochondria, and Ca signaling: implications for aging. J. Aging Res. 2011, 2011:920178.